Autonomic regulation of imbalance‑induced myocardial fibrosis and its mechanism in rats with cirrhosis

Yu,Shanshan; Sun,Lei; Wang,Hua; Jiang,Jue; Zhou,Qi

doi:10.3892/etm.2021.10472

Autonomic regulation of imbalance‑induced myocardial fibrosis and its mechanism in rats with cirrhosis

Authors:
- Shanshan Yu
- Lei Sun
- Hua Wang
- Jue Jiang
- Qi Zhou
View Affiliations

Affiliations: Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: July 21, 2021 https://doi.org/10.3892/etm.2021.10472
Article Number: 1040
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the changes in cardiac function and myocardial damage in rats with cirrhosis. In addition, a secondary aim was to explore any potential changes in the expression levels of β1‑adrenergic (β1) and muscarinic acetylcholine (M2) receptors . A cirrhotic cardiomyopathy (CCM) rat model was established by CCL4‑oil solution for subcutaneous injection into the neck. Pathological changes in the liver and myocardial tissues were detecting by H&E staining and Masson trichrome staining. Furthermore, changes in the levels of myocardial enzymes lactate dehydrogenase (LDH), creatine kinase isoenzyme (CK‑MB) and troponin in serum were measured by ELISA. The myocardial samples were homogenized and centrifuged. Subsequently, the supernatant was collected for detecting the expression of interleukins in myocardial tissue. Changes in the levels of inflammatory factors, IL‑1, IL‑2 and IL‑6 both in the serum and myocardial tissue were determined by ELISA. Changes in echocardiographic measurements were evaluated using high‑frequency ultrasound and the expression levels of β1 and M2 receptors in myocardial tissues were determined by western blotting. The normal lobular structure in liver tissues was found to be disappeared 8 weeks after modeling, which was replaced by pseudolobules in the rats in the CCM group. In addition, the myocardial cells were observed to be swollen and disorderly arranged. Compared with those in the control group, the left ventricular end‑systolic and end‑diastolic dimensions, interventricular septal dimension and LAD in rats in the CCM8 group were found to be significantly increased. The levels of myocardial enzymes LDH, CK‑MB and cardiac troponin in the serum were also revealed to be significantly increased in the CCM8 group. Additionally, the levels of IL‑1 and IL‑6 in both serum and myocardial tissues were significantly increased in rats in the CCM8 group. However, the levels of IL‑2 in both serum and myocardial tissues were decreased, which were observed alongside reductions in myocardial β1 and M2 receptor protein expression in the myocardial tissues. Taken together, these results indicate that inflammatory factors may be involved in mediating damage to the myocardium in rats with cirrhosis. During cirrhosis‑induced cardiac dysfunction, there may exist a mechanism for downregulation of autonomic nerve system.

View Figures

View References

1	Romanelli RG and Stasi C: Recent advancements in diagnosis and therapy of liver cirrhosis. Curr Drug Targets. 17:1804–1817. 2016.PubMed/NCBI View Article : Google Scholar
2	Tsochatzis EA, Bosch J and Burroughs AK: Liver cirrhosis. Lancet. 383:1749–1761. 2014.PubMed/NCBI View Article : Google Scholar
3	Kowalski HJ and Abelmann WH: The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 32:1025–1033. 1953.PubMed/NCBI View Article : Google Scholar
4	Ruiz-del-Arbol L and Serradilla R: Cirrhotic cardiomyopathy. World J Gastroenterol. 21:11502–11521. 2015.PubMed/NCBI View Article : Google Scholar
5	Khare J, Srivastava P, Wadhwa J and Deb P: Cardiac cirrhosis-an uncommon manifestation of common disease. OGH Reports. 6:28–30. 2017.
6	Jarkovska D, Bludovska M, Mistrova E, Krizkova V, Kotyzova D, Kubikova T, Slavikova J, Erek SN, Djordjevic A and Chottova Dvorakova M: Expression of classical mediators in hearts of rats with hepatic dysfunction. Can J Physiol Pharmacol. 95:1351–1359. 2017.PubMed/NCBI View Article : Google Scholar
7	Li X, Yu S, Li L, Han D, Dai S and Gao Y: Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score. Int J Clin Exp Med. 7:5751–5757. 2014.PubMed/NCBI
8	Cesari M, Fasolato S, Rosi S and Angeli P: Cardiac dysfunction in patients with cirrhosis: Is the systolic component its main feature? Eur J Gastroenterol Hepatol. 27:660–666. 2015.PubMed/NCBI View Article : Google Scholar
9	Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, Bettencourt P, Fraga J and Gama V: Systolic and diastolic dysfunction in cirrhosis: A tissue-Doppler and speckle tracking echocardiography study. Liver Int. 33:1158–1165. 2013.PubMed/NCBI View Article : Google Scholar
10	Gregolin CS, do Nascimento M, Borges de Souza SL, Ferreira Mota GA, Bomfim GF, de Azevedo Melo Luvizotto R, Sugizaki MM, Zanati Bazan SG, Salomé de Campos DH, Dias MC, et al: Myocardial dysfunction in cirrhotic cardiomyopathy is associated with alterations of phospholamban phosphorylation and IL-6 levels. Arch Med Res. 52:284–293. 2021.PubMed/NCBI View Article : Google Scholar
11	Silvestre OM, Farias AQ, Ramos DS, Furtado MS, Rodrigues AC, Ximenes RO, de Campos Mazo DF, Yoshimura Zitelli PM, Diniz MA, Andrade JL, et al: β-blocker therapy for cirrhotic cardiomyopathy: A randomized-controlled trial. Eur J Gastroenterol Hepatol. 30:930–937. 2018.PubMed/NCBI View Article : Google Scholar
12	Accornero F, van Berlo JH, Correll RN, Elrod JW, Sargent MA, York A, Rabinowitz JE, Leask A and Molkentin JD: Genetic analysis of connective tissue growth factor as an effector of transforming growth factor β signaling and cardiac remodeling. Mol Cell Biol. 35:2154–2164. 2015.PubMed/NCBI View Article : Google Scholar
13	Xiao H, Li H, Wang JJ, Zhang JS, Shen J, An XB, Zhang CC, Wu JM, Song Y, Wang XY, et al: IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. Eur Heart J. 39:60–69. 2018.PubMed/NCBI View Article : Google Scholar
14	Ziemssen T and Siepmann T: The investigation of the cardiovascular and sudomotor autonomis nervous system-a review. Front Neurol. 10(53)2019.PubMed/NCBI View Article : Google Scholar
15	Yang CH, Ting WJ, Day CH, Ju DT, Yeh YL, Chung LC, Tsai FJ, Tsai CH, Tsai Y and Huang CY: SHSST cyclodextrin complex prevents the fibrosis effect on CCl₄-induced cirrhotic cardiomyopathy in rats through TGF-β pathway inhibition effects. Int J Mol Sci. 15:8037–8048. 2014.PubMed/NCBI View Article : Google Scholar
16	Clark JD, Gebhart GF, Gonder JC, Keeling ME and Kohn DF: The 1996 guide for the care and use of laboratory animals. ILAR J. 38:41–48. 1997.PubMed/NCBI View Article : Google Scholar
17	Kasarala G and Tillmann H: Standard liver tests. Clin Liver Dis (Hoboken). 8:13–18. 2016.PubMed/NCBI View Article : Google Scholar
18	Lo RC and Kim H: Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatal. 23:302–307. 2017.PubMed/NCBI View Article : Google Scholar
19	Moller S and Henriksen JH: Cirrhotic cardiomyopathy. J Hepatol. 53:179–190. 2010.PubMed/NCBI View Article : Google Scholar
20	Naqvi IH, Mahmood K, Naeem M, Vashwani AS and Ziaullah S: The heart matters when the liver shatters! Cirrhotic cardiomyopathy: Frequency, comparison, and correlation with severity of disease. Prz Gastroenterology. 11:247–256. 2016.PubMed/NCBI View Article : Google Scholar
21	Berzigotti A: Advances and challenges in cirrhosis and portal hypertension. BMC Med. 15(200)2017.PubMed/NCBI View Article : Google Scholar
22	Chayanupatkul M and Liangpunsakul S: Cirrhotic cardiomyopathy: Review of pathophysiology and treatment. Hepatol Int. 8:308–315. 2014.PubMed/NCBI View Article : Google Scholar
23	Wang Y, Hu Y, Zeng Z, Li Y, Su H, Li Y, Wang R, Zhang M, Yang Y and Deng J: Influence of androgen on myocardial apoptosis and expression of myocardial IR and IRS1 in chronic heart failure rat models. Mol Med Rep. 17:1057–1064. 2018.PubMed/NCBI View Article : Google Scholar
24	Gassanov N, Caglayan E, Semmo N, Massenkeil G and Er F: Cirrhotic cardiomyopathy: A cardiologist's perspective. World J Gastroenterol. 20:15492–15498. 2014.PubMed/NCBI View Article : Google Scholar
25	Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, et al: Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol. 71:212–221. 2019.PubMed/NCBI View Article : Google Scholar
26	Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, Bedja D, Zhang H, Sheikh A, Margolick JB, et al: Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med. 211:1449–1464. 2014.PubMed/NCBI View Article : Google Scholar
27	Fede G, Privitera G, Tomaselli T, Spadaro L and Purrello F: Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol. 28:31–40. 2015.PubMed/NCBI
28	Karagiannakis DS, Papatheodoridis G and Vlachogiannakos J: Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci. 60:1141–1151. 2015.PubMed/NCBI View Article : Google Scholar
29	Liu H, Jayakumar S, Traboulsi M and Lee SS: Cirrhotic cardiomyopathy: Implications for liver transplantation. Liver Transpl. 23:826–835. 2017.PubMed/NCBI View Article : Google Scholar
30	Saner FH, Neumann T, Canbay A, Trechmann JW, Hartmann M, Goerlinger K, Bertram S, Beckebaum S, Cicinnati V and Paul A: High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int. 24:425–432. 2011.PubMed/NCBI View Article : Google Scholar
31	Yang YY and Lin HC: The heart: Pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc. 75:619–623. 2012.PubMed/NCBI View Article : Google Scholar
32	Zaky A and Lang JD: Cirrhosis-associated cardiomyopathy. J Anesth Clin Res. 3:1–7. 2012.
33	Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM, Cabrera-Muñoz ML, Méndez-Navarro J, Morán-Villota S and Dehesa-Violante M: Anatomical cardiac alterations in liver cirrhosis: An autopsy study. Ann Hepatol. 10:321–326. 2011.PubMed/NCBI
34	Naveed M, Han L, Hasnat M, Baig MMFA, Wang W, Mikrani R, Zhiwei L, Sembatya KR, Xie D and Zhou X: Suppression of TGP on myocardial remodeling by regulating the NF-κB pathway. Biomed Pharmacother. 108:1460–1468. 2018.PubMed/NCBI View Article : Google Scholar
35	Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I and Afonso L: Myocardial ﬁbrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: A meta-analysis. Heart. 101:1406–1411. 2015.PubMed/NCBI View Article : Google Scholar
36	Jou C, Shah R, Figueroa A and Patel JK: The role of inflammatory cytokines in cardiac arrest. J Intensive Care Med. 35:219–224. 2018.PubMed/NCBI View Article : Google Scholar
37	Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, Drinkhill MJ and Turner NA: Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism. FASEB J. 32:4941–4954. 2018.PubMed/NCBI View Article : Google Scholar
38	Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N and Montalto G: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 12:2563–2568. 2006.PubMed/NCBI View Article : Google Scholar
39	Liu X, Li C, Zhu J, Li W and Zhu Q: Dysregulation of FTX/miR-545 signaling pathway downregulates Tim-3 and is responsible for the abnormal activation of macrophage in cirrhosis. J Cell Biochem: Oct 10, 2018 (Epub ahead of print).
40	Pagourelias ED, Sotiriou P, Papadopoulos CE, Cholongitas E, Giouleme O and Vassilikos V: Left ventricular myocardial mechanics in cirrhosis: A speckle tracking echocardiographic study. Echocardiography. 33:223–232. 2016.PubMed/NCBI View Article : Google Scholar
41	Blendis L and Wong F: The hyperdynamic circulation in cirrhosis: An overview. Pharmacol Ther. 89:221–231. 2001.PubMed/NCBI View Article : Google Scholar
42	Moller S, Hove JD, Dixen U and Bendtsen F: New insights into cirrhotic cardiomyopathy. Int J Cardiol. 167:1101–1108. 2013.PubMed/NCBI View Article : Google Scholar
43	Muñoz-Ortega MH, Llamas-Ramírez RW, Romero-Delgadillo NI, Elías-Flores TG, Tavares-Rodríguez EJ, Campos-Esparza MR, Cervantes-García D, Muñoz-Fernández L, Gerardo-Rodríguez M and Ventura-Juárez J: Doxazasin treatment attenuates carbon tetrachloride-induced liver fibrosis in hamsters through a decrease in transforming growth factor β secretion. Gut Liver. 10:101–108. 2016.PubMed/NCBI View Article : Google Scholar
44	Communal C, Singh M, Menon B, Xie Z, Colucci WS and Singh K: Beta1integrins expression in adult rat ventricular myocytes and its role in the regulation of beta-adrenergic receptorstimulated apoptosis. J Cell Biochem. 89:381–388. 2003.PubMed/NCBI View Article : Google Scholar
45	Parvaneh S, Howe CL, Toosizadeh N, Honarvar B, Slepian MJ, Fain M, Mohler J and Najafi B: Regulation of cardiac autonomic nervous system control across frailty statuses: A systematic review. Gerontology. 62:3–15. 2016.PubMed/NCBI View Article : Google Scholar
46	Ma G, Wang Y, Hou D, Liu J, Zhang J, Xu L, Wang H, Zhao W, Zhang Y and Zhang L: Association of autoantibodies against the M2-muscarinic receptor with long-term outcomes in peripartum cardiomyopathy patients: A 5-year prospective study. J Cardiol. 74:251–257. 2019.PubMed/NCBI View Article : Google Scholar